Detection of hepatic steatosis using the controlled attenuation parameter: A comparative study with liver biopsy

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 5, 2014, Pages 611-616

  Yilmaz, Yusuf ^a   Yesil, Atakan ^b   Gerin, Fatma ^a   Ergelen, Rabia ^a   Akin, Hakan ^a   Celikel, Çigdem Ataizi ^a   Imeryuz, Nese ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Controlled attenuation parameter; Fibroscan; Hepatic steatosis; Nonalcoholic fatty liver disease

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ELASTOGRAPHY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; LIVER BIOPSY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; TURKEY (REPUBLIC); ULTRASOUND SCANNER; AREA UNDER THE CURVE; BIOPSY; CHRONIC DISEASE; ECHOGRAPHY; LIVER; MIDDLE AGED; PATHOLOGY; TURKEY; YOUNG ADULT;

ADULT; AGED; AREA UNDER CURVE; BIOPSY; CHRONIC DISEASE; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROC CURVE; TURKEY; YOUNG ADULT;

EID: 84899002185     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.881548     Document Type: Article

References (29)

1. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: Hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22:64-70. (Pubitemid 41564387
2. Matherly SC, Puri P. Mechanisms of simple hepatic steatosis: Not so simple after all. Clin Liver Dis 2012;16:505-24
3. KooSH.Nonalcoholic fatty liver disease:molecularmechanisms for the hepatic steatosis. Clin Mol Hepatol 2013;19:210-15
4. Wilkins T, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: Diagnosis and management. Am Fam Physician 2013;88:35-42
5. CampbellMS, Reddy KR. Review article: The evolving role of liver biopsy. Aliment Pharmacol Ther 2004;20:249-59
6. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: Is biopsy necessary?. Eur JGastroenterol Hepatol 2003;15:539-43
7. Browning JD. New imaging techniques for non-Alcoholic steatohepatitis. Clin Liver Dis 2009;13:607-19
8. Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Méndez-Sánchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 2008;7:212-20
9. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-45
10. Sasso M, Beaugrand M, deLedinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlledattenuationparameter(CAP):anovel VCTE- guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825-35
11. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): A novel tool for the noninvasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012;36:13-20
12. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(-): ValidationinchronichepatitisC.JViralHepat2012;19:244-53
13. MyersRP, PollettA, KirschR, Pomier-LayrarguesG, BeatonM, Levstik M, et al. Controlled Attenuation Parameter (CAP): A noninvasivemethod for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32:902-10
14. Boursier J, Calès P. Controlled attenuation parameter (CAP): A new device for fast evaluation of liver fat?. Liver Int 2012;32:875-7
15. de Lédinghen V, Vergniol J, Foucher J. Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-18
16. Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res 2013;37:305-10
17. Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis: Does etiology affect performance?. J Gastroenterol Hepatol 2013;28:1194-201
18. Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, et al. Utility of controlled attenuation parameter measurementfor assessing liver steatosis inJapanesepatientswith chronic liver diseases. Hepatol Res 2013;doi: 10.1111/ hepr.12094
19. Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population. Liver Int 2014;34:102-9
20. Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol 2013;25:1330-4
21. Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: Correlation with ultrasound. Liver Int 2013;doi: 10.1111/liv.12305
22. Yilmaz Y, Eren F, Colak Y, Senates E, Celikel CA, Imeryuz N. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2012;47:1488-93
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284
24. No authors listed]. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20
25. Emanuele E. Is biopsy always necessary?. Toward a clinicolaboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086-7
26. Yilmaz Y. Biomarkers for early detection of non-Alcoholic steatohepatitis: Implications for drug development and clinical trials. Curr Drug Targets 2013;14:1357-66
27. El-Zayadi AR. Hepatic steatosis: A benign disease or a silent killer. World J Gastroenterol 2008;14:4120-6
28. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013;267:422-31
29. Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, et al. Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013;267:767-75